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Abstract
Background: Docosahexaenoic acid (DHA, 22:6ω3) is a fundamental component of cell membranes, especially in
the brain and retina. In the experimental animal, DHA deficiency leads to suboptimal neurological performance
and visual deficiencies. Children with the Zellweger syndrome (ZS) have a profound DHA deficiency and symptoms
that can be attributed to their extremely low DHA levels. These children seem to have a metabolic defect in DHA
biosynthesis, which has never been totally elucidated. Treatment with DHA ethyl ester greatly improves these
patients, but if we could normalize their endogenous DHA production we could get additional benefits. We
examined whether DHA biosynthesis by Δ4-desaturation could be enhanced in the human species by transfecting
the enzyme, and if this could normalize the DHA levels in cells from ZS patients.
Results: We showed that the Δ4-desaturase gene (Fad4) from Thraustochytrium sp, which can be expressed by
heterologous transfection in other plant and yeast cells, can also be transfected into human lymphocytes, and that
it expresses the enzyme (FAD4, Δ4-desaturase) by producing DHA from direct Δ4-desaturation of 22:5ω3. We also
found that the other substrate for Δ4-desaturase, 22:4ω6, was parallely desaturated to 22:5ω6.
Conclusions: The present “in vitro” study demonstrates that Δ4-desaturase can be transfected into human cells
and synthesize DHA (as well as 22:5ω6, DPA) from 22:5ω3 and 22:4ω6, respectively, by putative Δ4-desaturation.
Even if this pathway may not be the physiological route for DHA biosynthesis “in vivo”, the present study opens
new perspectives for the treatment of patients within the ZS spectrum.
Background
Docosahexaenoic acid (DHA, 22:6ω3) is a polyunsatu-
rated fatty acid (PUFA) of fundamental importance in
cell membranes, especially in nerve endings and the
photoreceptor cells in the retina [1,2]. DHA is consid-
ered essential during brain development, especially after
31 weeks of gestation, when its accretion is maximal [3].
In the clinical setting, DHA deficiency has been related
to several human diseases [4].
In the human species, it is generally agreed that synth-
esis of DHA from its essential precursor 18:3ω3( a-lino-
lenic acid) is inadequate, especially in the premature
infant, where it does not cover the daily needs of this
important PUFA. Because of that, DHA is being added
to many infant formulas during the last years. Even in
the adult, DHA is being increasingly recommended to
improve several conditions, with more or less convin-
cing basis and results. Thus, based on its marginally
decreased levels, DHA is currently being recommended
as a supplement for such varied diseases as attention
deficit hyperactivity disorder [5], fetal alcohol syndrome
[6], phenylketonuria [7], schizophrenia [8], unipolar
depression [9], aggressive behavior [10], Alzheimer’s dis-
ease [11] and diabetes [12]. However, it is only in one
group of diseases -the Zellweger syndrome and its
related phenotypes- where the DHA levels are dramati-
cally diminished in all tissues, including the brain and
retina [13,14].
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ger syndrome spectrum, usually called peroxisomal
biogenesis disorders (PBD), are lethal congenital diseases,
characterized by the lack of functional peroxisomes in
the cells of the body [15]. As a consequence, several bio-
chemical reactions related to lipid metabolism, which
normally occur in the peroxisome, are affected. Among
them, b-oxidation of pristanic and very long chain fatty
acids (VLCFA) [16], as well as a-oxidation of phytanic
acid [17], are defective. Biosynthesis of plasmalogens
[18] and biliary acids is also defective [19]. In addition,
we found that these children show a profound DHA
deficiency [13,14]. In classic Zellweger’s syndrome (ZS),
the prototype of these disorders, brain DHA levels may
be so low as to only account for 20-25% of the normal
values [3,13], and in the Zellweger retina, DHA is
virtually absent [14].
Clinically, these patients become blind, deaf, and
mentally retarded very early in life. Myelin is always
defective in classic Zellweger’s syndrome (ZS), in both
amount and quality (dysmyelination), and liver function
is consistently impaired. Renal cysts are commonly
added, which gave the name of cerebro-hepato-renal
syndrome to the first ZS patients described [20,21] The
life span of these patients is very short, especially in
classic ZS, where survival rarely surpasses the first year
of age. There are milder Zellweger variants, known as
neonatal adrenoleukodystrophy (NALD) and infantile
Refsum’s disease (IRD). These relatively milder pheno-
types, however, present most of the symptoms of classic
ZS, including profound mental retardation with myelina-
tion delay, followed later by demyelination, visual and
hearing sensorineural defects and liver involvement.
There is no means to differentiate the various ZS phe-
notypes, when based on genotype or biochemical
abnormalities alone. They are mainly clinical entities,
with extremely variable organ involvement and prog-
nosis. Without a treatment and special care, however,
all these patients live very short lives, rarely reaching
older childhood. In spite of that, correcting their DHA
deficiency produces substantial benefits in their myelina-
tion [22], liver function [23] and vision [24], thus
prolonging survival and quality of life markedly.
We believe that DHA deficiency plays a crucial role in
this group of congenital disorders, as most of the
patients’ symptoms are consistent with what is found
in DHA-deficient animals [25] and humans [26]. ZS
patients - even more than normal children - are prob-
ably incapable of producing all the DHA required by the
fast development of their brain and retina.
There is some controversy about the mechanism of
DHA biosynthesis in mammals. Classically, it was
accepted that DHA is formed by front-end, putative
Δ4-desaturation of its immediate precursor 22:5ω3, by
introducing a double bond in position Δ4( c o u n t i n g
from the carboxyl end, IUPAC nomenclature). In paral-
lel, this enzyme would also convert 22:4ω6t o2 2 : 5 ω6
(ω6 docosapentaeoic acid, DPA). In lower eukaryotes,
like the Thraustochytrium sp,t h ee x i s t e n c eo fa
Δ4-desaturase has been demonstrated. When expressed
in yeast (Saccharomyces cerevisiae) and plants (Brassica
juncea),t h i se n z y m eΔ4-desaturates 22:5ω3 to 22:6ω3
[27]. This results in the controlled production of doco-
sahexaenoic acid, an interesting method for the nutra-
ceutical industry, given the decreasing supply of DHA
from natural, marine products.
In mammals, this pathway has practically been aban-
doned and an alternate route involving the peroxisome
has been generally accepted [28]. This route would
imply the microsomal elongation of 22:5ω3 to 24:5ω3,
followed by a second Δ6-desaturation step to 24:6ω3,
which would finally be b-oxidated in the peroxisome to
produce DHA. Again, the same route would work for
the ω6 family, finally yielding 22:5ω6 from 24:5ω6.
Whether or not humans have an intrinsic Δ4-desaturase
remains unknown. Nevertheless, the present paper
shows for the first time that the Δ4-desaturation path-
way is functional in the human species when cells are
transfected with the enzyme. We show that when the
gene that codes for this enzyme (Fad4) is transfected
into human lymphocytes immortalized with the Epstein-
Barr virus (EBV), putative Δ4-desaturation of both sub-
strates, 22:5ω3a n d2 2 : 4 ω6, is produced, yielding DHA
and DPA, respectively, as their products.
Results
Transfection of the FlagΔ4 desaturase gene
As an example, Fig. 1 shows one of the control EBV
immortalized lymphocyte lines, transiently transfected
with the plasmid carrying the Δ4-desaturase gene (pIRE-
S2EGFP-FlagΔ4 construct) on day 3 after electropora-
tion. Upper (A) and lower (B) panels show the cells
under bright field and fluorescence microscopy, respec-
tively. By comparing both images and by direct counting
of the cells in the various cases studied, we could esti-
mate that the transfection efficiency was quite low,
widely varying between 5 and 25%.
Lymphocyte fatty acid composition
It must be pointed out that the fatty acid patterns are
deeply altered when lymphocytes are immortalized with
the EBV. Table 1 shows the main differences. Among
PUFA, it can be seen that the proportion of arachidonic
acid (AA, 20:4ω6) is much lower in EBV immortalized
lymphocytes (as is the 20:4ω6/20:3ω6r a t i o )t h a ni nt h e
normal, circulating cells, whereas that of ω3 fatty acids
is higher. This can be due to the multiple manipulations
suffered by these cells and/or to the fetal calf serum
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lar occurs in human cultured skin fibroblasts, where the
ω6/ω3 proportion is lower and the ratio 22:6ω3/22:5ω3
is very close to one. This is not what happens in fresh
human cells, where DHA clearly predominates. As cul-
tured cells, bovine serum is known to have lower ω6/ω3
and 22:6ω3/22:5ω3 ratios than human plasma and this
can influence the composition of human cells nourished
with it. However, the advantages of obtaining great
amounts of immortalized lymphocytes by far outweigh
this drawback. Besides, a high proportion of 22:5ω3i s
an advantage when we want to know its possible con-
version to DHA. Other marked differences, although
probably of less biological importance, are the much
higher percentage of monounsaturated fatty acids in
EBV immortalized lymphocytes than in fresh cells.
Omega-9, but also ω7 fatty acids, are many times higher
in EBV immortalized lymphocytes than in fresh cells,
something that we have also found in cultured skin
fibroblasts (data not shown).
Fig. 2 visually shows the effects of transfecting the
enzyme in a normal child and a patient with Zellweger’s
syndrome. Even by just looking at the gas chromato-
grams, it can be seen that Δ4-desaturation of the
precursor 22:5ω3( ω3DPA) to 22:6ω3 (DHA) always
occurred in the gene-transfected cells (B) when com-
pared to those transfected with the empty vector (A).
However, this Δ4-desaturation effect was clearly greater
in the Zellweger-syndrome patients than in normal chil-
dren. Without adding the enzyme, the 22:6ω3/22:5ω3
ratio was usually greater than 1.0 in the normal controls,
whereas in ZS patients, there was an inversion of the
normal situation, DHA being lower than ω3DPA. After
transfecting the Δ4-desaturation gene, however, all cells
showed a 22:6ω3/22:5ω3 ratio clearly higher than 1.0. It
must be emphasized that the changes observed were
due to the transfected enzyme, not to any nutritional
differences, the only DHA and ω3DPA added to the
medium being those contained in the fetal calf serum,
which was constant in all cases.
Table 2 shows the complete list of lymphocyte fatty
acids in control and PBD patient cells, without the
Figure 1 Microscopic images of human immortalized
lymphocytes transfected with the Δ4-desaturase vector. Human
B lymphoblastoid cells from one of the control cases, transiently
transfected with the pIRES2EGFP-FlagΔ4 vector on day 3 after
electroporation. Upper (A) and lower (B) panels show the cells
under bright field and fluorescence microscopy, respectively.
Table 1 Comparison between the main fatty acid
composition of freshly obtained human lymphocytes and
lymphoblastoid cell lines transfected with the empty
vector
Fresh EBV immortalized
14:0 0.49 2.06
16:0 19.59 21.06
16:1ω9 0.28 2.21
16:1ω7 0.28 1.27
18:0 19.72 15.66
18:1ω9 15.30 19.29
18:1ω7 1.68 7.29
18:2ω6 7.49 2.75
18:3ω6 0.03 0.09
18:3ω3 0.09 0.06
20:0 1.00 0.25
20:1ω9 0.64 1.45
20:3ω9 0.10 0.74
20:3ω6 1.65 3.21
20:4ω6 19.79 7.06
20:5ω3 0.31 0.58
22:4ω6 2.13 1.23
22:5ω6 0.37 0.31
22:5ω3 1.34 4.20
22:6ω3 2.01 4.46
ω6/ω3 7.72 1.41
22:6ω3/22:5ω3 1.50 1.06
22:5ω6/22:4ω6 0.17 0.26
20:4ω6/20:3ω6 11.99 2.20
22:4ω6/20:4ω6 0.11 0.17
This table compares the main fatty acid composition (mol%) of freshly
processed human lymphocytes with that of lymphoblastoid cell lines
immortalized with the Epstein-Barr virus and transfected with the empty
plasmid pIRES2EGFP (mean). Note the very different arachidonic acid content
of fresh and treated cells. In contrast, the ω3 PUFAs are higher and the
22:6ω3/22:5ω3 ratio is comparatively lower in the processed cells. Also, note
the higher values of ω9a n dω7 fatty acids in the EBV-treated cells.
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when the Δ4-desaturase gene was transfected. The sta-
tistical significance of the different fatty acids is shown.
Only the mono and poly-unsaturated fatty acids change
significantly between the two groups. As expected, the
ratio of 22:6ω3t o2 2 : 5 ω3w a sl o w e ri nt h eZ Sp a t i e n t
group, at a very high level of statistical significance
(p value lower than 0.0001). A similar change in the
22:5ω6/22:4ω6 ratio was observed, which was very sig-
nificantly lower in the ZS patients than in controls.
Figs. 3 and 4 show these ratios individually. It can be
seen that both ratios increased when the Δ4-desaturase
gene was epitopically expressed. Despite the low trans-
fection efficiency, there was no case without a response
of both ω3a n dω6 PUFA precursors. Again, the ZS
patients showed a greater effect of the enzyme. This
effect was variable due to the wide phenotype heteroge-
neity, as well as the variations inherent to the methods
used. Nevertheless, the enzyme action was evident even
more clearly in the patients than in controls, with all
the changes showing an extremely high statistical
significance (p < 0.0001) by paired t-tests. In most cases,
the 22:5ω6/22:4ω6 ratio increased even more than the
22:6ω3/22:5ω3 ratio, although its variability was higher.
This supports the hypothesis that Δ4-desaturase is a
common enzyme in this pathway, by introducing a dou-
ble bond in 22:5ω3, as well as in 22:4ω6.
Some of these changes did not reach statistical signifi-
cance when all the cases were grouped in controls and
ZS patients (tables 2 and 3) because any individual var-
iation was masked by grouping. This is especially true
for the 22:5ω6/22:4ω6 ratio, whose variability was the
largest, as can be seen in fig. 4. On the whole, though,
these data show that, starting at lower values in the ZS
patients, Δ4-desaturation of both ω3a n dω6l o n g
PUFAs normalized after expressing the gene (tables 2
and 3 and Figs. 3 and 4). This is better illustrated in
Figs. 5 and 6, which compare the number of times that
the 22:6ω3/22:5ω3a n d2 2 : 5 ω6/22:4ω6 ratios, respec-
tively, increased in controls and ZS patients (see legends
to the figures). By expressing the results that way, even
grouping did not mask the very significant differences
Figure 2 Gas-chromatographic differences of the main omega-3 PUFAs between the normal and the Zellweger-syndrome child.
Omega-3 VLPUFA peaks directly scanned from the gas chromatograms in one control and one ZS patient. It can be seen that, before adding
the Δ4-desaturase construct (A), DHA is higher than ω3DPA (22:5ω3) in the normal child, while it is lower than ω3DPA in the patient with
Zellweger’s syndrome (ratio 22:6ω3/22:5ω3 < 1.0) When adding the enzyme (B), this ratio increases clearly, especially in the ZS patient.
Martinez et al. Lipids in Health and Disease 2010, 9:98
http://www.lipidworld.com/content/9/1/98
Page 4 of 10between controls and ZS patients, which were larger in
the case of the 22:5ω6/22:4ω6 ratio.
Discussion
Currently, the Δ4-desaturation pathway has been disre-
garded as an operative route in mammals. This has
mainly been due to the fact that the corresponding
enzyme has never been characterized. Also, the finding
that DHA is decreased in Zellweger-syndrome patients
[13] promoted the study of an alternate route linking
the defective VLCFA b-oxidation in ZS patients to their
DHA deficiency [28]. This is a very attractive concept,
and is consistent with the fact that 24:6ω3i sc o n v e r t e d
to DHA when b-oxidation of VLCFA is intact, which is
not the case in peroxisomal-disorder patients. That
DHA is readily produced from 24:6ω3i sa ni n c o n t e s t -
able fact, as we have checked by adding this very long
PUFA (VLPUFA) to cells in culture (data not shown).
Table 2 Fatty acid composition of lymphoblastoid cell
lines transfected with the empty vector, in healthy
controls and in patients with the Zellweger syndrome
Controls Zellweger syndrome
Fatty acid Mean ± SEM N Mean ± SEM N Statistics
12:0 0.13 ± 0.011 16 0.27 ± 0.049 14 n.s.
14:0 2.06 ± 0.122 16 1.87 ± 0.101 14 n.s.
16:0 21.06 ± 0.343 16 21.58 ± 0.231 14 n.s.
16:1ω9 2.21 ± 0.100 16 2.03 ± 0.070 14 n.s.
16:1ω7 1.27 ± 0.082 16 1.13 ± 0.058 14 n.s.
18:0 15.66 ± 0.220 16 16.91 ± 0.315 14 P < 0.005
18:1ω9 19.29 ± 0.482 16 17.01 ± 0.761 14 P < 0.05
18:1ω7 7.29 ± 0.190 16 6.27 ± 0.275 14 P < 0.01
18:2ω6 2.75 ± 0.113 16 2.42 ± 0.076 14 P < 0.05
18:3ω6 0.09 ± 0.006 16 0.05 ± 0.015 14 n.s.
18:3ω3 0.06 ± 0.008 16 0.03 ± 0.009 14 n.s.
20:0 0.25 ± 0.010 16 0.27 ± 0.015 14 n.s.
20:1ω6 1.45 ± 0.071 16 1.66 ± 0.182 14 n.s.
20:2ω6 0.36 ± 0.017 16 0.42 ± 0.029 14 n.s.
20:3ω9 0.74 ± 0.048 16 0.65 ± 0.035 14 n.s.
20:3ω6 3.21 ± 0.108 16 2.64 ± 0.142 14 P < 0.005
20:4ω6 7.06 ± 0.328 16 8.36 ± 0.696 14 n.s.
20:5ω3 0.58 ± 0.042 16 0.49 ± 0.052 14 n.s.
22:0 0.32 ± 0.018 16 0.32 ± 0.022 14 n.s.
22:1ω9 0.25 ± 0.023 16 0.39 ± 0.028 14 P < 0.001
22:4ω6 1.23 ± 0.083 16 2.15 ± 0.168 14 P < 0.0001
22:5ω6 0.31 ± 0.018 16 0.25 ± 0.021 14 P < 0.05
22:5ω3 4.2 ± 0.218 16 4.88 ± 0.233 14 P < 0.005
22:6ω3 4.46 ± 0.173 16 3.91 ± 0.085 14 P < 0.01
24:0 0.41 ± 0.017 16 0.48 ± 0.021 14 P < 0.005
24:1ω9 0.94 ± 0.073 16 0.86 ± 0.078 14 P < 0.005
26:0 0.05 ± 0.009 16 0.14 ± 0.015 14 P < 0.0001
26:1ω9 0.15 ± 0.020 16 0.38 ± 0.044 14 P < 0.0001
24:4ω6 0.02 ± 0.007 16 0.03 ± 0.022 13 n.s.
24:5ω6 0.02 ± 0.007 16 0.14 ± 0.038 13 P < 0.005
24:5ω3 0.02 ± 0.008 16 0.06 ± 0.023 13 n.s.
24:6ω3 0.08 ± 0.014 16 0.15 ± 0.043 13 n.s.
22:6ω3/22:5ω3 1.07 ± 0.020 16 0.83 ± 0.046 14 P < 0.0001
22:5ω6/22:4ω6 0.28 ± 0.018 16 0.12 ± 0.011 14 P < 0.0001
This table is a list of the mean values ± SEM of total fatty acids (mol%) and
their main ratios in human lymphocytes transfected with the empty plasmid
(pIRES2EGFP), in normal controls as well as in Zellweger-syndrome patients.
P values are only shown for statistically significant changes.
Table 3 Fatty acid composition of lymphoblastoid cell
lines transfected with the Δ4-desaturase vector, in
healthy controls and in patients with the Zellweger
syndrome
Controls Zellweger syndrome
Fatty acid Mean ± SEM N Mean ± SEM N Statistics
12:0 0.12 ± 0.021 16 0.24 ± 0.057 14 n.s.
14:0 1.75 ± 0.124 16 1.80 ± 0.103 14 n.s.
16:0 21.49 ± 0.239 16 21.58 ± 0.396 14 n.s.
16:1ω9 2.13 ± 0.096 16 1.99 ± 0.066 14 n.s.
16:1ω7 1.12 ± 0.077 16 1.12 ± 0.066 14 n.s.
18:0 15.60 ± 0.202 16 16.83 ± 0.326 14 P < 0.005
18:1ω9 18.45 ± 0.439 16 17.25 ± 0.756 14 n.s.
18:1ω7 7.09 ± 0.136 16 6.34 ± 0.265 14 n.s.
18:2ω6 2.73 ± 0.122 16 2.43 ± 0.085 14 n.s.
18:3ω6 0.11 ± 0.020 16 0.05 ± 0.015 14 n.s.
18:3ω3 0.06 ± 0.012 16 0.04 ± 0.009 14 n.s.
20:0 0.31 ± 0.050 16 0.27 ± 0.016 14 n.s.
20:1ω9 1.37 ± 0.071 16 1.69 ± 0.179 14 n.s.
20:2ω6 0.37 ± 0.019 16 0.39 ± 0.017 14 n.s.
20:3ω9 0.70 ± 0.065 16 0.64 ± 0.050 14 n.s.
20:3ω6 3.39 ± 0.083 16 2.68 ± 0.145 14 P = 0.0001
20:4ω6 7.69 ± 0.306 16 8.34 ± 0.681 14 n.s.
20:5ω3 0.56 ± 0.049 16 0.55 ± 0.073 14 n.s.
22:0 0.32 ± 0.023 16 0.30 ± 0.022 14 n.s.
22:1ω9 0.25 ± 0.017 16 0.39 ± 0.021 14 P < 0.0001
22:4ω6 1.19 ± 0.078 16 1.57 ± 0.139 14 P < 0.05
22:5ω6 0.56 ± 0.031 16 0.75 ± .053 14 P < 0.005
22:5ω3 3.58 ± 0.202 16 3.21 ± 0.157 14 n.s.
22:6ω3 5.56 ± 0.149 16 5.63 ± 0.159 14 n.s.
24:0 0.37 ± 0.011 16 0.47 ± 0.053 14 n.s.
24:1ω9 0.79 ± 0.072 16 0.86 ± 0.057 14 n.s.
26:0 0.06 ± 0.018 16 0.16 ± 0.029 14 P < 0.01
26:1ω9 0.11 ± 0.012 16 0.33 ± 0.027 14 P < 0.0001
24:4ω6 0.02 ± 0.008 16 0.01 ± 0.007 13 n.s.
24:5ω6 0.02 ± 0.011 16 0.11 ± 0.019 13 P = 0,0002
24:5ω3 0.03 ± 0.007 16 0.01 ± 0.005 13 P < 0.05
24:6ω3 0.07 ± 0.015 16 0.12 ± 0.010 13 P < 0.05
22:6ω3/22:5ω3 1.62 ± 0.096 16 1.82 ± 0.129 14 n.s.
22:5ω6 22:4ω6 0.52 ± 0.048 16 0.53 ± 0.064 14 n.s.
This table lists the mean values ± SEM of total fatty acids (mol%) and their
main ratios in immortalized lymphocytes transfected with the Δ4-desturase
plasmid (pIRES2EGFP-FlagΔ4), in normal controls as compared with Zellweger-
syndrome patients. As in table 2, p values are only shown for statistically
significant changes.
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24:6ω3 ,w h i l et h i sP U F Ai sn o r m a l l yp r e s e n to n l yi n
trace amounts in human cells. Whether or not this is
due to rapid metabolism of 24:6ω3 (and its counterpart
of the ω6 family 24:5ω6) remains to be demonstrated. A
recent paper [29] suggests that both are simple runaway
elongation by-products. Yet, even if these VLPUFAs
were the main (or even the only) route for the synthesis
of DHA (and 22:5ω6), the present paper shows that, by
transfecting the gene that codes for Δ4-desaturase
(Fad4), this classic, putative Δ4-desaturation route is
also operative in the human species.
This may be important for patients within the Zellwe-
ger syndrome spectrum (ZS, NALD, IRD). Indeed, if
DHA deficiency is a primary defect in these patients,
normalization of its biosynthesis could cause even more
beneficial effects than treatment with DHA alone. Even
if quantitatively small, we do not know if endogenous
DHA synthesis in the liver is of prevalent importance in
the healthy human. Some data in the rat suggest so [30].
Normalizing plasma and erythrocyte DHA levels in ZS
patients is quite easy, usually also leading to an increase
in plasmalogen synthesis and in VLCFA b-oxidation,
together with marked improvements in liver function
tests [23]. However, once normalized, maintaining the
right levels is quite critical, especially with the very high
doses of ω3 PUFAs that are currently recommended.
This may easily lead to PUFA imbalance, with an unde-
sirable and dangerous decrease in the ω6 PUFAs, mainly
arachidonic acid (AA, 20:4ω6). AA is an important pre-
cursor in prostaglandin and leukotriene biosynthesis and
there may be other abnormalities, whose consequences
w ed on o tc u r r e n t l yk n o w .I tm u s ta l s ob ep o i n t e do u t
that most of the triglyceride DHA preparations com-
mercially in use nowadays have linoleic acid (18:2ω6)
added in the form of sunflower oil. This neutralizes the
effects of DHA and may also add to the blockage of AA
biosynthesis by an excess of precursor. Besides, giving
too much DHA may block its own biosynthesis, by
negative feedback caused by an excess of the product.
These facts are not normally taken into account, and
DHA is lately widely recommended without even look-
ing at the subject’s fatty acid changes.
In summary, this paper shows that adding Δ4-desaturase
to human cells greatly increases the production of both
DHA and 22:5ω6 (DPA). The latter is known to increase
Figure 3 Omega-3 individual effects of transfection with Δ4-desaturase on controls and children with the Zellweger syndrome.T h i s
figure shows the significant increases of the 22:6ω3/22:5ω3 ratio in all the children transfected with the Δ4-desaturase plasmid. As can be seen,
the ratio increases clearly in all the cases. However, the slope is higher in the ZS patients, whose ratio is lower from the start and surpasses the
normal in some patients. The greater variability in the ZS patients is due to their clinical and biological heterogeneity. Yet, the statistical
significance of paired t-tests is extremely high in all cases (p < 0.0001)
Figure 4 Omega-6 individual effects of transfection with Δ4-desaturase on controls and children with the Zellweger syndrome.T h i s
figure shows the significant increases in the 22:5ω6/22:4ω6 ratio in all the children transfected with the Δ4-desaturase vector. As can be seen,
the ratio increases clearly in all the cases (p value lower than 0.0001 by paired t-tests). Again, the slope is higher in the ZS patients, who start
with lower ratios than the controls. Here too, the ZS patients show a greater variability in the ratio, although the statistical significance remains
extremely high.
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its biochemical structure is very similar to DHA. This
VLPUFA was also diminished in the ZS patients, and its
increase when we added the Δ4-desaturase construct sup-
ports the view that this route is functional for both series
of PUFAs. Therefore, the changes obtained seem to be
more physiological than simply adding DHA to the diet.
Even if the conditions we used were “in vitro” experiments
in human EBV immortalized lymphocytes, the results
were of an extremely high statistical significance, and we
believe that they warrant the continuation of this work.
Perhaps introducing Δ4-desaturase into these patients by
genetic engineering could lead to normalization of the
DHA (and 22:5ω6) biosynthesis in patients with the Zell-
weger syndrome and other peroxisome biogenesis disor-
ders. This may be highly beneficial for these patients.
Conclusions
This paper shows for the first time that, by transfecting
human cells with the gene coding for Δ4-desaturase
(Fad4), these cells can express the enzyme as lower
eukaryotes do. This leads to an increased biosynthesis of
DHA and DPA in healthy subjects, and to normalization
of the DHA deficiency in Zellweger’s syndrome, together
with an increase in DPA. Although this is only an
“in vitro” study in human cells, it opens new avenues
for research on human fatty acid metabolism and the
possibility of devising a new treatment for these life-
threatening diseases.
Methods
Human subjects
Blood samples from 14 children with generalized peroxi-
somal disorders and 16 normal controls were used for
the present study. The age range was similar in both
cases (3 months to 12 years, for peroxisomal disorders,
and 2 months to 14 years, for controls). The clinical
severity of the peroxisomal-disorder patients was highly
variable, including two cases with classic Zellweger’s
syndrome and 12 cases within the neonatal adrenoleu-
kodystrophy/infantile Refsum’s disease (NALD/IRD)
spectrum. Control samples were obtained from normal
children in the occasion of blood drawings performed
for routine analyses. They had no abnormalities, with
the exception of a small baby with a suspect diagnosis
of non-ketotic hyperglycinemia, who could not be analy-
tically distinguished from the rest of controls. Parental
consent was obtained in all cases. Peripheral blood was
drawn after a minimum of 6 hours of fasting and col-
lected in EDTA tubes. The preferred volume was 3 ml,
but in small children, as little as 1 ml was used. Proces-
sing of samples was started immediately in all cases.
Never were the cells or plasma frozen before starting
the procedure, since it was found that some PUFAs may
be degraded by freezing and thawing, especially in ery-
throcytes. Centrifugation was carried out at 2330 × g for
10 minutes. Plasma was removed, and the buffy coat
and some adjacent red blood cells and remaining plasma
were collected. The process was repeated after re-
suspending and washing the erythrocyte pellet with
about 5 ml of saline solution, trying to completely
Figure 5 Omega-3 effects of transfection with Δ4-desaturase
on grouped controls and patients with the Zellweger
syndrome. The number of times that the 22:6ω3/22:5ω3 ratio
increased when the Δ4-desaturase construct was transfected, in
normal children and in ZS patients, is displayed here. For that, a
new index was obtained by dividing the 22:6ω3/22:5ω3 ratio with
the added Δ4-desaturase by the same ratio obtained when
transfecting the empty vector [(22:6ω3/22:5ω3)+Δ4/(22:6ω3/22:5ω3)
empty]. Bars are mean values ± SEM. Despite the effect of grouping
patients and controls by unpaired t-tests, the statistical significance
was still extremely high (p = 0.0002).
Figure 6 Omega-6 effects of transfection with Δ4-desaturase
on grouped controls and patients with the Zellweger
syndrome. This figure displays the number of times that the
22:5ω6/22:4ω6 ratio increased when adding the Δ4-desaturase, in
normal children, as well as in the ZS patients. A new index was
obtained by dividing the 22:5ω6/22:4ω6 ratio with the Δ4-
desaturase added by the same ratio without the enzyme [(22:5ω6/
22:4ω6)+Δ4/(22:5ω6/22:4ω6) empty]. Bars are mean values ± SEM.
Despite the effect of grouping patients and controls by unpaired
t-tests, the statistical significance was still very high (p = 0.0009).
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Solution Gradient (Rafer) was used to isolate peripheral
blood mononuclear cells (PBMC) from the white cell
layer, according to the manufacturer’s instructions. The
fatty acid composition of the removed plasma and
washed erythrocytes was separately determined as the
routine control of the patients (data not shown), as well
as to check the fatty acid status of the normal subjects.
Establishment of the B lymphoblastoid cell lines (BLCL)
Lymphoblastoid cell lines were established by Epstein-
Barr Virus (EBV) transformation/infection of peripheral
blood mononuclear cells (PBMC) in the presence of
phytohemagglutinin (PHA) [31]. PBMCs were incubated
with B95-8 cell supernatant (containing Epstein-Barr
virus (EBV) in the presence of 10 μg/mL of PHA in
RPMI1640 supplemented with 20% (v/v) heat inacti-
vated, fetal calf serum (FCS), 2 mM of L-Glutamine, 100
units/mL of penicillin, 100 μg/mL of streptomycin and
0.5 μg/mL of Amphotericin B (Gibco, Invitrogen). Cells
were plated on 24-well plates and were incubated at
37°C, 5% CO2 until the growth of the B lymphoblastoid
cell lines (BLCL) was established. Thereafter, cells were
expanded and routinely grown in RPMI1640 culture
medium supplemented with 10% heat inactivated FCS,
2 mM of L-Glutamine, 100 units/mL of penicillin and
100 μg/mL of streptomycin.
Generation of the pM2Δ4 vector
The open reading frame of the Thraustochytrium sp
Δ4 desaturase (Fad4) was identified and cloned from a
cDNA library of Thraustochytrium sp [27]. To generate
pM2Δ4, the cDNA fragment was released by a BamHI/
EcoRI double digestion and inserted into the BglII/
EcoRI double digested eukaryotic expression vector pM2
under the control of the constitutive SV40 early
promoter.
Generation of pIRES2EGFP-FlagΔ4 vector
Preliminary experiments were performed co-trasfecting
the pM2Δ4 or empty pM2 together with the pIRES2
EGFP vector as a control for efficency of transfection.
Initially, Lipofectamine LTX (Invitrogen) was used as
the transfection reagent. This produced a slight increase
in the desaturase activity in the pM2Δ4 transfected cells
with respect to the ones transfected with the empty
pM2 vector. However, with these conditions, the
Δ4-desaturase activity was too small to reach statistical
significance. Moreover, the fatty acid composition of the
cells was affected by the use of lipofectamine LTX, as
shown in the empty pM2 vector transfected cells (data
not shown). To circunvent this, electroporation was
chosen as the method for transfection.
To better monitor the transfection efficiency, the cod-
ing sequence of Fad4 was cloned into the pIRES2EGFP
vector. The mammalian expression vector pIRES2EGFP
contains an Internal Ribosome Entry Site (IRES) between
the MCS and the EGFP coding region that would permit
both the Fad4 and the EGFP to be translated from a sin-
gle bicistronic mRNA. Moreover, it also contains the
Human cytomegalovirus (CMV) immediate early promo-
ter. The CMV promoter has been shown to be stronger
in B lymphoid cell lines than the SV40 promoter [32]. To
further increase the translation efficiency in eukaryotic
cells, a Kozak consensus translation initiation site was
included. A flag sequence was added to allow the detec-
tion of the expressed FAD4 desaturase in the transfected
cells. To achieve that, the Thraustochytrium sp Δ4c D N A
was amplified by PCR using the plasmid pM2Δ4a sa
template. Restriction sites were added to the 5′ ends of
both PCR primers to allow further cloning. The forward
primer was designed to contain a BglII restriction site
(underlined), a Kozak consensus sequence, the ATG start
codon (bold), and a Flag tag sequence (italic), as follows:
5′-AAAGATCTCCACCATGGACTACAAGGACGAC-
GATGACAAGGGCAGCGGCACGGTCGGCTACGAC-
GAG-3′. Reverse primer contained a EcoRI site
(underlined) and a stop codon (bold), and it was:
5′-AGGAATTCAGGCAGCGCGCTGC-3′.T h eP C R
reaction was performed using Phusion High-Fidelity
DNA Polymerase (Finnzymes). The conditions were: an
initial denaturation of 1 min. at 98 °C, followed by 30
cycles of 10 s at 98°C, 12 s at 54°C, and 1 min at 72°C,
and a final extension of 7 min at 72°C. The 1.6 kb PCR-
amplified DNA fragment was isolated by electrophoresis
using 0.8% agarose, gel-purified using NucleoSpin
Extract II (MACHEREY-NAGEL), and, following diges-
tion with BglII and EcoRI restriction enzymes (Takara),
cloned into BglI/EcoRI-digested pIRES2EGFP to gener-
ate the construct pIRES2EGFP-FlagΔ4. To rule out the
presence of PCR-generated mutations, the entire insert
and flanking regions were sequenced using the BigDye®
Terminator v3.1 Cycle Sequencing Kit (Applied Biosys-
tems), and an Applied Biosystems Model 3730 DNA
Analyzer. The CodonCode Aligner software was used
for alignment and analysis of the sequences. The coding
sequence was identical to that in pM2Δ4.
Expression of FlagΔ4-desaturase protein
To confirm the functionality of the pIRES2EGFP-FlagΔ4
vector, the recombinant plasmid was used to transfect
the colon cancer cell line HCT116, and overexpression
of the 60 kDa Flag-FAD4 was confirmed by Western
blotting (data not shown). Functional activity of the
Δ4-desaturase was not affected by the Flag tag, since the
pIRES2EGFP-FlagΔ4 construct restored desaturase
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out the tag (pIRES2EGFP-Δ4) (data not shown).
Transfection of the B lymphoblastoid cell lines
Plasmid pIRES2EGFP-FlagΔ4 was used to transfect
BLCLs. 40 μg of DNA were electroporated at 250 V and
950 μFi n t o6 - 1 0×1 0
7 cells in 0.4 cm cuvettes (Gene
Pulser × cell, BioRad). Cells were plated into 6-well
plates and grown in RPMI-1640 medium supplemented
with 20% FCS. In each case, electroporation of pIRE-
S2EGFP was done in parallel and used as a control. On
day 3 after transfection, EGFP expression was confirmed
using an inverse fluorescence microscope (Leica DM IL
LED), and alive cells were purified by centrifugation
upon Lymphocytes Isolation Solution Gradient (Rafer).
A small fraction was separated for protein quantifica-
tion, and the rest of the cells were pelleted and
subjected to fatty acid analysis. Protein quantification
was carried out using the BCA Protein Assay Kit
(Pierce) with Bovine serum albumin (BSA) as the
protein standard.
Fatty acid analysis
The final lymphocyte pellet was directly used for fatty
acid analysis. In our experience, measuring the total
fatty acid content of a sample is the best to evaluate its
PUFA composition. This allows direct methanolysis of
the sample, and loses are minimized.
Thus, total lipids (and plasmalogens) were directly
transmethylated from the washed lymphocyte pellet
with HCl-methanol, basically by the method of Lepage
and Roy [33] with slight variations [14]. In order to
check the linearity of the flame ionization detector (FID)
in each analysis, two internal standards of widely differ-
ent molecular weights (13:0 and 23:0) were used instead
of one. Only when the areas of the two internal stan-
dards were close enough (within ≤ 10% variation) were
the results considered acceptable.
Briefly, 1.95 ml of methanol-benzene 4:1 (v/v) and
50 μl of the internal standard mixture (in the same sol-
vent), containing 25 μg of each internal standard, was
added to the cell pellet in a methanolysis, Corning tube.
After slowly adding 0.2 ml of acetyl chloride while con-
tinuously vortexing the tube, the tightly stopped tube
was placed in a dry bath at 100°C for an hour. After
cooling, 5 ml of 6% K2CO3 was added to neutralize the
acid. After centrifuging at 2330 × g for 10 minutes, the
clear supernatant was ready for direct injection into
the gas chromatograph. When the protein content of
the sample was too low, the supernatant was concen-
trated under a stream of N2 i nas m a l lg l a s st u b ea n d
injected immediately. Never was the concentrate stored
in the freezer or refrigerator for later use, since this was
found to decrease the PUFA levels.
The total fatty acid methyl esters (FAME) were sepa-
rated on a 30 m long, 0.25 mm ID RTX-2330 capillary
column, programmed between 140°C and 200-220°C, at
variable rates (2°-4° C/minute) according to the state of
the column, until the whole spectrum of fatty acids was
resolved. When necessary, a second RTX-2330 and a
30 m long 0.2 mm ID, BPX70 column was used to
check the results. Three different Hewlett Packard gas
chromatographs were used for these columns: one 6890
and two 5890-II. The carrier gas was helium, at rates of
0.8-1.2, depending on the column type and state. Injec-
tor and detector temperatures were 250°C and 260°C,
respectively. When necessary, the identity of some peaks
of interest was confirmed by mass spectrometry using a
Hewlett Packard, 5970B mass spectrometer. Quantita-
tion of fatty acids was performed with Merck Hitachi,
2000 and 2500, computer-integrators. Quantitative data
were referred to mg of protein. However, percent values
were preferred, due to the large protein variability of the
cells.
Statistical analysis
The statistical differences were analyzed by Student
t-tests. Two types of analyses were performed, paired
and unpaired t tests. To estimate the Δ4-desaturase
activity we used simple product/precursor ratios, that is,
22:6ω3/22:5ω3 for DHA synthesis, and 22:5ω6/22:4ω6
for formation of the ω6 docosapentaenoic acid (DPA).
These two ratios were evaluated in the cells transfected
with the empty plasmid (pIRES2EGFP) and in those
transfected with the Δ4c o n s t r u c t( p I R E S 2 E G F P -
FlagΔ4). To diminish the individual variability a paired
t-test was used for this evaluation (Figs. 3 and 4).
Unpaired t-tests were used for grouping comparisons
between patients and controls (Tables 2 ad 3, and
Figs. 5 and 6). GraphPad Prism 4 and t-test calculator
(GraphPad Sofware) were used as the software.
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